JPH0341096A - インシュリン様成長因子類の結合蛋白 - Google Patents

インシュリン様成長因子類の結合蛋白

Info

Publication number: JPH0341096A
Authority: JP; Japan
Prior art keywords: binding protein; igf; fragment; dna; sequence
Prior art date: 1988-11-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP1293772A

Other languages

English (en)

Japanese (ja)

Inventor

Christopher Binkert

クリストフェル・ビンケルト

Gunther F Heinrich

ギュンテル・エフ・ハインリッヒ

Jurg Schwander

ユールグ・シュバンデル

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-11

Filing date

1989-11-10

Publication date

1991-02-21

1989-11-10 Application filed by Sandoz AG filed Critical Sandoz AG

1991-02-21 Publication of JPH0341096A publication Critical patent/JPH0341096A/ja

Status Pending legal-status Critical Current

Links

108091008324 binding proteins Proteins 0.000 title claims description 77
108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract description 12
102000013275 Somatomedins Human genes 0.000 title abstract description 6
102000023732 binding proteins Human genes 0.000 title 1
102000014914 Carrier Proteins Human genes 0.000 claims abstract description 80
210000004027 cell Anatomy 0.000 claims description 43
239000002299 complementary DNA Substances 0.000 claims description 39
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 34
102100037852 Insulin-like growth factor I Human genes 0.000 claims description 34
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 34
102000028416 insulin-like growth factor binding Human genes 0.000 claims description 23
108091022911 insulin-like growth factor binding Proteins 0.000 claims description 23
239000012634 fragment Substances 0.000 claims description 22
108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
125000003275 alpha amino acid group Chemical group 0.000 claims description 17
230000012010 growth Effects 0.000 claims description 16
150000001413 amino acids Chemical class 0.000 claims description 12
108020004414 DNA Proteins 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
238000009396 hybridization Methods 0.000 claims description 7
239000013598 vector Substances 0.000 claims description 7
230000029663 wound healing Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
230000004936 stimulating effect Effects 0.000 claims description 6
230000017423 tissue regeneration Effects 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000033667 organ regeneration Effects 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
210000003527 eukaryotic cell Anatomy 0.000 claims description 3
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
210000001236 prokaryotic cell Anatomy 0.000 claims description 2
108020004511 Recombinant DNA Proteins 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
239000002699 waste material Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 11
108010078791 Carrier Proteins Proteins 0.000 abstract description 4
230000001225 therapeutic effect Effects 0.000 abstract description 4
108090000623 proteins and genes Proteins 0.000 description 30
241000700159 Rattus Species 0.000 description 28
235000018102 proteins Nutrition 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
230000027455 binding Effects 0.000 description 16
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
210000004185 liver Anatomy 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 11
239000002243 precursor Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000002609 medium Substances 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
230000001605 fetal effect Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 9
102000004877 Insulin Human genes 0.000 description 8
108090001061 Insulin Proteins 0.000 description 8
229940125396 insulin Drugs 0.000 description 8
150000007523 nucleic acids Chemical group 0.000 description 8
239000000523 sample Substances 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 7
210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 6
238000010586 diagram Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
102000008186 Collagen Human genes 0.000 description 5
108010035532 Collagen Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000003636 conditioned culture medium Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000010828 elution Methods 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000035772 mutation Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 4
108010051696 Growth Hormone Proteins 0.000 description 4
102100038803 Somatotropin Human genes 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
239000000122 growth hormone Substances 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000002297 mitogenic effect Effects 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
238000012261 overproduction Methods 0.000 description 4
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
208000008839 Kidney Neoplasms Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
206010038389 Renal cancer Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
230000022159 cartilage development Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000006870 function Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
201000010982 kidney cancer Diseases 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000011164 ossification Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
XWNXEWLCHSLQOI-UHFFFAOYSA-K trisodium;triacetate Chemical compound [Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O XWNXEWLCHSLQOI-UHFFFAOYSA-K 0.000 description 3
238000001262 western blot Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
239000006137 Luria-Bertani broth Substances 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
208000012868 Overgrowth Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
206010038934 Retinopathy proliferative Diseases 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
210000004381 amniotic fluid Anatomy 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000002608 insulinlike Effects 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
238000013519 translation Methods 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
239000003357 wound healing promoting agent Substances 0.000 description 2
JCVDICFLPGDHAT-DJLDLDEBSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,5-dimethylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 JCVDICFLPGDHAT-DJLDLDEBSA-N 0.000 description 1
UQFMGLLQCSSNQM-UHFFFAOYSA-N 2-(phenylcarbamoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC(=O)NC1=CC=CC=C1 UQFMGLLQCSSNQM-UHFFFAOYSA-N 0.000 description 1
XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 description 1
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
101001044255 Entamoeba histolytica Amoebiasin-2 Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100036284 Hepcidin Human genes 0.000 description 1
101000585553 Homo sapiens Glycodelin Proteins 0.000 description 1
101001021253 Homo sapiens Hepcidin Proteins 0.000 description 1
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
101000835862 Homo sapiens Mothers against decapentaplegic homolog 1 Proteins 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229910001323 Li2O2 Inorganic materials 0.000 description 1
102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
241000920340 Pion Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
208000030555 Pygmy Diseases 0.000 description 1
239000012614 Q-Sepharose Substances 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
108090000244 Rat Proteins Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241001672648 Vieira Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000006687 ag medium Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
238000003491 array Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000002648 chondrogenic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
210000003275 diaphysis Anatomy 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000006377 glucose transport Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000036124 hormone binding proteins Human genes 0.000 description 1
108091011044 hormone binding proteins Proteins 0.000 description 1
102000048444 human PAEP Human genes 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000009290 primary effect Effects 0.000 description 1
239000013615 primer Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000000623 ulna Anatomy 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Biophysics (AREA)
Ophthalmology & Optometry (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP1293772A 1988-11-11 1989-11-10 インシュリン様成長因子類の結合蛋白 Pending JPH0341096A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8826451		1988-11-11
GB888826451A GB8826451D0 (en)	1988-11-11	1988-11-11	Improvements in/relating to organic compounds

Publications (1)

Publication Number	Publication Date
JPH0341096A true JPH0341096A (ja)	1991-02-21

Family

ID=10646720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP1293772A Pending JPH0341096A (ja)	1988-11-11	1989-11-10	インシュリン様成長因子類の結合蛋白

Country Status (16)

Country	Link
EP (1)	EP0369943B1 (fi)
JP (1)	JPH0341096A (fi)
AT (1)	ATE112311T1 (fi)
AU (1)	AU623447B2 (fi)
CA (1)	CA2002609A1 (fi)
DE (1)	DE68918556D1 (fi)
DK (1)	DK564989A (fi)
FI (1)	FI895346A0 (fi)
GB (1)	GB8826451D0 (fi)
HU (2)	HU895607D0 (fi)
IL (1)	IL92257A0 (fi)
MY (1)	MY104673A (fi)
NZ (1)	NZ231333A (fi)
PL (1)	PL162290B1 (fi)
PT (1)	PT92278B (fi)
ZA (1)	ZA898610B (fi)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5258287A (en) *	1988-03-22	1993-11-02	Genentech, Inc.	DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5212074A (en) *	1990-08-28	1993-05-18	Chiron Corporation	Genetic material encoding new insulin-like growth factor binding protein igfbp-6
EP0546081A4 (en) *	1990-08-28	1994-08-17	Chiron Corp	New insulin-like growth factor binding protein (igfbp-4)
EP0546074B1 (en) *	1990-08-28	2001-11-14	Chiron Corporation	Genetic material encoding igfbp-5
US6326154B1 (en)	1990-11-19	2001-12-04	Genentech, Inc.	Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) *	1990-11-19	1993-05-11	Genentech, Inc.	Ligand-mediated immunofunctional hormone binding protein assay method
EP0556344B1 (en) *	1991-01-08	2003-08-13	Chiron Corporation	New insulin-like growth factor binding protein
US5187151A (en) *	1991-02-12	1993-02-16	Genentech, Inc.	Use of binding protein with igf-i as an anabolic growth promoting agent
US6124259A (en) *	1993-01-28	2000-09-26	Celtrix Pharmaceuticals, Inc.	Method for treating ophthalmic disorders with IGFBP
AU6626794A (en) *	1993-04-07	1994-10-24	Amgen Boulder Inc.	Methods of using insulin-like growth factor binding proteins
JPH09507832A (ja) *	1993-09-20	1997-08-12	セルトリックスファーマシューティカルズ，インコーポレイテッド	Ｉｇｆｂｐ単独またはｉｇｆｂｐとｉｇｆとの複合体による免疫疾患および血液疾患の処置
SE9303784D0 (sv) *	1993-11-16	1993-11-16	Kabi Pharmacia Ab	Igf
US6121416A (en)	1997-04-04	2000-09-19	Genentech, Inc.	Insulin-like growth factor agonist molecules
US6420518B1 (en)	1997-04-04	2002-07-16	Genetech, Inc.	Insulin-like growth factor agonist molecules
IL143834A0 (en)	1999-01-06	2002-04-21	Genentech Inc	Insulin-like growth factor (igf) i mutant variants
AU762351B2 (en)	1999-01-06	2003-06-26	Genentech Inc.	Insulin-like growth factor (IGF) I mutant variants
ES2301547T3 (es)	2000-05-16	2008-07-01	Genentech, Inc.	Tratamiento de trastornos del cartilago.
AU2002248609B2 (en)	2001-03-14	2007-03-01	Genentech, Inc.	IGF antagonist peptides
ES2527871T3 (es)	2003-05-01	2015-02-02	Imclone Llc	Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
NZ545940A (en)	2003-09-12	2009-12-24	Tercica Inc	Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
EP1670822A2 (en)	2003-10-03	2006-06-21	Genentech, Inc.	Igf binding proteins
DK2100614T3 (da)	2005-06-17	2013-10-28	Imclone Llc	Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
WO2007092453A2 (en)	2006-02-03	2007-08-16	Imclone Systems Incorporated	Igf-ir antagonists as adjuvants for treatment of prostate cancer
PE20201166A1 (es)	2017-09-11	2020-10-28	Shire Human Genetic Therapies	Metodos y composiciones para tratar enfermedades pulmonares cronicas
KR20230113287A (ko)	2020-10-19	2023-07-28	오크 힐 바이오 리미티드	신생아에 사용하기에 적합한 조성물
MX2024008819A (es)	2022-01-19	2024-09-17	Oak Hill Bio Ltd	Composiciones y metodos para reducir la oxidacion de igf-1/igfbp.
WO2023242439A1 (en)	2022-06-17	2023-12-21	Oak Hill Bio Limited	Vascular stabilisation (preterm infants)
WO2023242440A1 (en)	2022-06-17	2023-12-21	Oak Hill Bio Limited	Treament of lungs in infants
WO2023242442A1 (en)	2022-06-17	2023-12-21	Oak Hill Bio Limited	Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2024170612A1 (en)	2023-02-14	2024-08-22	Oak Hill Bio Limited	Treatment of healing dysregulation in gi tissue

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK131988A (da) *	1988-03-11	1989-09-12	Erasmus University	Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
EP0418230B1 (en) *	1988-04-12	1995-12-27	Amgen Boulder Inc.	Method for potentiating and inhibiting insulin-like growth factor activity

1988
- 1988-11-11 GB GB888826451A patent/GB8826451D0/en active Pending
1989
- 1989-10-30 HU HU895607A patent/HU895607D0/hu unknown
- 1989-11-08 EP EP89810845A patent/EP0369943B1/en not_active Expired - Lifetime
- 1989-11-08 DE DE68918556T patent/DE68918556D1/de not_active Expired - Lifetime
- 1989-11-08 AT AT89810845T patent/ATE112311T1/de not_active IP Right Cessation
- 1989-11-08 HU HU895836A patent/HUT53936A/hu unknown
- 1989-11-09 CA CA002002609A patent/CA2002609A1/en not_active Abandoned
- 1989-11-09 FI FI895346A patent/FI895346A0/fi not_active Application Discontinuation
- 1989-11-09 MY MYPI89001562A patent/MY104673A/en unknown
- 1989-11-09 IL IL92257A patent/IL92257A0/xx unknown
- 1989-11-09 AU AU44536/89A patent/AU623447B2/en not_active Ceased
- 1989-11-09 NZ NZ231333A patent/NZ231333A/en unknown
- 1989-11-10 ZA ZA898610A patent/ZA898610B/xx unknown
- 1989-11-10 PL PL89282257A patent/PL162290B1/pl unknown
- 1989-11-10 PT PT92278A patent/PT92278B/pt not_active IP Right Cessation
- 1989-11-10 DK DK564989A patent/DK564989A/da not_active Application Discontinuation
- 1989-11-10 JP JP1293772A patent/JPH0341096A/ja active Pending

Also Published As

Publication number	Publication date
MY104673A (en)	1994-05-31
HUT53936A (en)	1990-12-28
AU4453689A (en)	1990-06-07
ZA898610B (en)	1991-07-31
DK564989A (da)	1990-05-12
PT92278A (pt)	1990-05-31
DE68918556D1 (de)	1994-11-03
HU895836D0 (en)	1990-01-28
DK564989D0 (da)	1989-11-10
PT92278B (pt)	1995-09-12
NZ231333A (en)	1992-10-28
EP0369943B1 (en)	1994-09-28
FI895346A0 (fi)	1989-11-09
PL162290B1 (pl)	1993-09-30
ATE112311T1 (de)	1994-10-15
GB8826451D0 (en)	1988-12-14
EP0369943A1 (en)	1990-05-23
CA2002609A1 (en)	1990-05-11
HU895607D0 (en)	1990-01-28
AU623447B2 (en)	1992-05-14
IL92257A0 (en)	1990-07-26

Publication	Publication Date	Title
JPH0341096A (ja)	1991-02-21	インシュリン様成長因子類の結合蛋白
US5607918A (en)	1997-03-04	Vascular endothelial growth factor-B and DNA coding therefor
JP4219404B2 (ja)	2009-02-04	新規なアグーティ関連遺伝子
US5928939A (en)	1999-07-27	Vascular endothelial growth factor-b and dna coding therefor
US6689580B1 (en)	2004-02-10	Growth factor
EP0559769B1 (en)	2001-02-07	Heparin binding mitogen with homology to epidermal growth factor (egf)
JP2541761B2 (ja)	1996-10-09	ミュレル管抑制物質様ポリペプチドおよびその製造方法
IE66495B1 (en)	1996-01-10	Bone morphogenetic protein
JPH09118695A (ja)	1997-05-06	組換え繊維芽細胞成長因子
EP0546110B1 (en)	2001-11-14	New insulin-like growth factor binding protein igfbp-5
JP2002526073A (ja)	2002-08-20	新規のヒト生長分化因子のコード配列、そのｄｎａ配列によりコードされるポリペプチド、およびこれらの製造方法。
JP4776774B2 (ja)	2011-09-21	心血管疾患の予防及び治療用オステオプロテゲリン含有組成物
KR20020047208A (ko)	2002-06-21	섬유소용해 활성을 갖는 폴리펩티드
EP0546074B1 (en)	2001-11-14	Genetic material encoding igfbp-5
JP2000502569A (ja)	2000-03-07	Ｏｂタンパク質レセプター及び関連組成物と関連方法
KR19990022716A (ko)	1999-03-25	골 자극 인자
US6329500B1 (en)	2001-12-11	Transforming growth factor-β binding site